KemPharm (NASDAQ:KMPH) Lifted to “Buy” at Zacks Investment Research
Zacks Investment Research upgraded shares of KemPharm (NASDAQ:KMPH) from a hold rating to a buy rating in a research report report published on Tuesday, Zacks.com reports. The brokerage currently has $1.00 price target on the specialty pharmaceutical company’s stock.
According to Zacks, “KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States. “
Other research analysts have also issued reports about the company. HC Wainwright reissued a buy rating and issued a $3.00 price objective on shares of KemPharm in a report on Thursday, September 5th. Oppenheimer cut their price objective on KemPharm from $8.00 to $3.00 and set an outperform rating on the stock in a report on Thursday, May 23rd. ValuEngine raised KemPharm from a sell rating to a hold rating in a report on Thursday, August 1st. Finally, Roth Capital lowered KemPharm from a buy rating to a neutral rating and cut their price objective for the company from $4.25 to $1.05 in a report on Thursday, September 5th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. KemPharm currently has an average rating of Buy and a consensus price target of $2.01.
KemPharm (NASDAQ:KMPH) last announced its quarterly earnings data on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.09. Analysts forecast that KemPharm will post -1.15 earnings per share for the current year.
Several hedge funds have recently made changes to their positions in the company. RDA Financial Network acquired a new stake in KemPharm during the second quarter worth about $28,000. BlackRock Inc. grew its holdings in KemPharm by 21.7% during the second quarter. BlackRock Inc. now owns 106,490 shares of the specialty pharmaceutical company’s stock worth $186,000 after acquiring an additional 19,001 shares during the period. Iowa State Bank grew its holdings in KemPharm by 90.6% during the second quarter. Iowa State Bank now owns 44,171 shares of the specialty pharmaceutical company’s stock worth $77,000 after acquiring an additional 21,000 shares during the period. Geode Capital Management LLC grew its holdings in KemPharm by 136.7% during the fourth quarter. Geode Capital Management LLC now owns 171,047 shares of the specialty pharmaceutical company’s stock worth $304,000 after acquiring an additional 98,775 shares during the period. Finally, Vanguard Group Inc. grew its holdings in KemPharm by 134.5% during the second quarter. Vanguard Group Inc. now owns 1,337,571 shares of the specialty pharmaceutical company’s stock worth $2,341,000 after acquiring an additional 767,100 shares during the period. 26.73% of the stock is currently owned by institutional investors and hedge funds.
KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder.
See Also: Risk Tolerance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.